Table 5.
Demographic and Clinical Characteristics of the Hypoalgesic and Other UC cohorts
| Variable | Hypoalgesic UC | Other UC | P value |
| Cohort (% women) | 41 (39.0%) | 114 (51.8%) | 0.16 |
| Age (yr) | 48.1 ± 2.6 | 46.1 ± 1.4 | 0.48 |
| BMI | 26.2 ± 0.7 | 29.2 ± 1.2 | 0.15 |
| Race (AI-AN/Asian/BoAA/White) | 1/2/1/37 | 1/4/5/104 | 0.79 |
| Disease location (Montreal) | |||
| E1 | 3 (7.3%) | 7 (6.1%) | 0.68 |
| E2 | 9 (22.0%) | 33 (28.9%) | |
| E3 | 29 (70.7%) | 77 (65.0%) | |
| Disease duration (yr) | 9.4 ± 1.6 | 11.9 ± 0.9 | 0.17 |
| Any history of EIM | 11 (26.8%) | 53 (46.5%) | 0.03 |
| Short Inflammatory Bowel Disease Questionnaire | 56.7±1.9 | 43.6±1.4 | <0.001 |
| Pain scores (SIBDQ4 = 6/SIBDQ4 = 7) | 14/27 | ||
| Short Clinical Colitis Activity Index | 2.7±0.4 | 4.6±0.3 | 0.002 |
| Laboratory studies | |||
| WBC (103 cells/mm3) | 8.8 ± 0.6 | 8.2 ± 0.4 | 0.16 |
| ESR (mm/hr) | 22.0 ± 4.1 | 19.3 ± 2.0 | 0.73 |
| CRP (mg/dL) | 1.5 ± 0.5 | 1.6 ± 0.3 | 0.60 |
| Current IBD medications | |||
| Corticosteroid | 5 (12.2%) | 19 (16.7%) | 0.50 |
| Mesalamine | 25 (61.0%) | 38 (33.3%) | 0.003 |
| Immunomodulator | 9 (22.0%) | 22 (19.3%) | 0.82 |
| Biologic | 16 (39.0%) | 54 (47.4%) | 0.36 |
| Active pain medication/substance use | |||
| Tobacco | 4 (9.8%) | 10 (8.8%) | 0.99 |
| Alcohol | 12 (29.3%) | 34 (29.8%) | 1.0 |
| Cannabis | 1 (2.4%) | 6 (5.3%) | 0.68 |
| NSAID | 6 (14.6%) | 27 (23.7%) | 0.27 |
| Opioid | 2 (4.9%) | 16 (14.0%) | 0.16 |
| Illicit drug | 1 (2.4%) | 8 (7.0%) | 0.45 |
| Other pain medications | 10 (24.4%) | 57 (50.0%) | 0.006 |
| Symptoms of anxiety/depression | 8 (19.5%) | 58 (50.9%) | <0.001 |
| Antidepressant/anxiolytic use | 5 (12.2%) | 33 (28.9%) | 0.04 |
AI-AN, American Indian-Alaska Native; BMI, body mass index; BoAA, Black or African American; CRP, C-reactive protein; EIM, extraintestinal manifestation; ESR, sedimentation rate; NSAID, nonsteroidal anti-inflammatory drug; IBD, inflammatory bowel disease; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; SIBDQ4, SIBDQ Pain Score (note: a SIBDQ4 score of 6 indicates abdominal pain hardly any of the time over the prior 2 wk period, while a score of 7 indicates no pain); UC, ulcerative colitis.
Items in bold-italics demonstrated statistically significant differences from one another.